BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Du Y, Liu D, Du Y. Recent advances in hepatocellular carcinoma therapeutic strategies and imaging-guided treatment. J Drug Target 2021;:1-15. [PMID: 34727794 DOI: 10.1080/1061186X.2021.1999963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Sun Y, Yang J, Li Y, Luo J, Sun J, Li D, Wang Y, Wang K, Yang L, Wu L, Sun X. Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC. Mol Cancer 2022;21:212. [PMID: 36457016 DOI: 10.1186/s12943-022-01681-y] [Reference Citation Analysis]
2 Zou X, Li T, Mao Y, Zhu M, Chen X, Niu J, Dong T, Jiang J, Yang X. Multifunctional Drug-Loaded Phase-Change Nanoparticles Inhibit the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma by Affecting the Activity of Activated Hepatic Stellate Cells. BioMed Research International 2022;2022:1-18. [DOI: 10.1155/2022/6441179] [Reference Citation Analysis]
3 Liu H, Qin X, Xu Z, Wu M, Lu T, Zhou S, Yao N, Liu S, Shao Y, Han Z. Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China. Front Genet 2022;13:1000448. [DOI: 10.3389/fgene.2022.1000448] [Reference Citation Analysis]